Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 9/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953355 | 0.91 | PDPK1 (0.61) | DGAT1KCNH2NPBWR1KDRPDPK1 | |
| SCHEMBL5952873 | 0.88 | CNR1 (0.56) | DGAT1KCNH2NPBWR1KDRPDPK1 | |
| SCHEMBL5952146 | 0.88 | PDE10A (0.53) | DGAT1KCNH2NPBWR1CHEK1 | |
| SCHEMBL4916396 | 0.88 | PDE10A (0.53) | DGAT1KCNH2NPBWR1CHEK1 | |
| SCHEMBL5952104 | 0.87 | NPC1 (0.52) | DGAT1KCNH2KDRTRPV1TNKS | |
| SCHEMBL5952465 | 0.85 | RUNX1 (0.49) | DGAT1KCNH2TRPV1CBFBCHEK1 | |
| SCHEMBL5953232 | 0.84 | ITK (0.52) | DGAT1KCNH2NPBWR1KDRTNKS | |
| SCHEMBL5952686 | 0.84 | NPC1 (0.50) | NPBWR1KDRTRPV1TNKSTNKS2 | |
| SCHEMBL5951223 | 0.84 | MEN1 (0.50) | DGAT1NPBWR1KDRTNKSTNKS2 | |
| SCHEMBL5952707 | 0.81 | CYP1A2 (0.48) | DGAT1KCNH2PDPK1TRPV1CBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | DGAT1 4531/4885KCNH2 627/4885NPBWR1 4340/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | DGAT1 4380/4885KCNH2 665/4885NPBWR1 3858/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | DGAT1 3639/4885KCNH2 708/4885NPBWR1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.